1250 related articles for article (PubMed ID: 19926371)
21. Predicting mortality and uptake of renal replacement therapy in patients with stage 4 chronic kidney disease.
Conway B; Webster A; Ramsay G; Morgan N; Neary J; Whitworth C; Harty J
Nephrol Dial Transplant; 2009 Jun; 24(6):1930-7. PubMed ID: 19181760
[TBL] [Abstract][Full Text] [Related]
22. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
[TBL] [Abstract][Full Text] [Related]
23. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
24. Nonsurgical weight loss for extreme obesity in primary care settings: results of the Louisiana Obese Subjects Study.
Ryan DH; Johnson WD; Myers VH; Prather TL; McGlone MM; Rood J; Brantley PJ; Bray GA; Gupta AK; Broussard AP; Barootes BG; Elkins BL; Gaudin DE; Savory RL; Brock RD; Datz G; Pothakamuri SR; McKnight GT; Stenlof K; Sjöström LV
Arch Intern Med; 2010 Jan; 170(2):146-54. PubMed ID: 20101009
[TBL] [Abstract][Full Text] [Related]
25. Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation.
Chitalia N; Raja RB; Bhandara T; Agrawal P; Kaski JC; Jha V; Banerjee D
J Nephrol; 2010; 23(1):77-84. PubMed ID: 20091490
[TBL] [Abstract][Full Text] [Related]
26. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
27. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort.
Levin A; Djurdjev O; Beaulieu M; Er L
Am J Kidney Dis; 2008 Oct; 52(4):661-71. PubMed ID: 18805347
[TBL] [Abstract][Full Text] [Related]
28. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R
Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
[TBL] [Abstract][Full Text] [Related]
29. An association between body mass index and estimated glomerular filtration rate.
Kawamoto R; Kohara K; Tabara Y; Miki T; Ohtsuka N; Kusunoki T; Yorimitsu N
Hypertens Res; 2008 Aug; 31(8):1559-64. PubMed ID: 18971530
[TBL] [Abstract][Full Text] [Related]
30. Combination of diet, exercise and intermittent treatment of cimetidine on body weight and maintenance of weight loss. A 42 months follow-up study.
Birketvedt GS; Thom E; Bernersen B; Florholmen J
Med Sci Monit; 2000; 6(4):699-703. PubMed ID: 11208394
[TBL] [Abstract][Full Text] [Related]
31. Randomized trial assessing the impact of a musculoskeletal intervention for pain before participating in a weight management program.
Snow R; Ruane J; LaLonde M; Shaffer L; Kim B; Graffagnino C; Falko J; Spencer K; Caulin-Glaser T
J Cardiopulm Rehabil Prev; 2010; 30(3):173-80. PubMed ID: 20040884
[TBL] [Abstract][Full Text] [Related]
32. Family Weight School treatment: 1-year results in obese adolescents.
Nowicka P; Höglund P; Pietrobelli A; Lissau I; Flodmark CE
Int J Pediatr Obes; 2008; 3(3):141-7. PubMed ID: 18608623
[TBL] [Abstract][Full Text] [Related]
33. The impact of self-management support on the progression of chronic kidney disease--a prospective randomized controlled trial.
Chen SH; Tsai YF; Sun CY; Wu IW; Lee CC; Wu MS
Nephrol Dial Transplant; 2011 Nov; 26(11):3560-6. PubMed ID: 21414969
[TBL] [Abstract][Full Text] [Related]
34. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.
Klahr S; Levey AS; Beck GJ; Caggiula AW; Hunsicker L; Kusek JW; Striker G
N Engl J Med; 1994 Mar; 330(13):877-84. PubMed ID: 8114857
[TBL] [Abstract][Full Text] [Related]
35. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification.
Poston WS; Reeves RS; Haddock CK; Stormer S; Balasubramanyam A; Satterwhite O; Taylor JE; Foreyt JP
Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1486-93. PubMed ID: 14634679
[TBL] [Abstract][Full Text] [Related]
36. Weight loss in obese patients with chronic kidney disease: who and how?
Teta D
J Ren Care; 2010 May; 36 Suppl 1():163-71. PubMed ID: 20586912
[TBL] [Abstract][Full Text] [Related]
37. Body mass index and the risk of progression of chronic kidney disease.
Khedr A; Khedr E; House AA
J Ren Nutr; 2011 Nov; 21(6):455-61. PubMed ID: 21454093
[TBL] [Abstract][Full Text] [Related]
38. Effect of intradialytic versus home-based aerobic exercise training on physical function and vascular parameters in hemodialysis patients: a randomized pilot study.
Koh KP; Fassett RG; Sharman JE; Coombes JS; Williams AD
Am J Kidney Dis; 2010 Jan; 55(1):88-99. PubMed ID: 19932545
[TBL] [Abstract][Full Text] [Related]
39. Effect of orlistat-assisted weight loss on endothelium-dependent vasodilation in obese Chinese subjects with hypertension.
Liu J; Sun N; Yang S; Ma Z; Yang J
Clin Exp Hypertens; 2010; 32(6):395-9. PubMed ID: 20804448
[TBL] [Abstract][Full Text] [Related]
40. 12-month outcomes and process evaluation of the SHED-IT RCT: an internet-based weight loss program targeting men.
Morgan PJ; Lubans DR; Collins CE; Warren JM; Callister R
Obesity (Silver Spring); 2011 Jan; 19(1):142-51. PubMed ID: 20523304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
